Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge.
Antiviral immunity
CD8(+) T cells
IFNAR
Innate immunity
LCMV
Viral vaccine vectors
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
22 02 2021
22 02 2021
Historique:
received:
23
07
2020
revised:
07
12
2020
accepted:
16
01
2021
pubmed:
2
2
2021
medline:
22
5
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
Reverse genetically engineered recombinant lymphocytic choriomeningitis virus (rLCMV) is a novel vaccine vector platform. Here, we investigate the safety and efficacy of rLCMV in mice lacking a functional type I interferon system with high susceptibility to viral infections. Propagation-deficient rLCMV vector expressing ovalbumin as a model antigen is cleared from type I interferon receptor-deficient mice (Ifnar
Identifiants
pubmed: 33518468
pii: S0264-410X(21)00074-8
doi: 10.1016/j.vaccine.2021.01.047
pii:
doi:
Substances chimiques
Vaccines, Synthetic
0
Viral Vaccines
0
Receptor, Interferon alpha-beta
156986-95-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1257-1264Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.